Link to this page
COVID-19 Ontology
| Preferred Name | Tacrolimus | |
| Synonyms |
Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone FK 506 Fujimycin Hecoria Prograf Protopic TACROLIMUS Tacrolimus tacrolimus |
|
| Definitions |
A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1311 |
|
| Accepted_Therapeutic_Use_For |
Atopic dermatitis; Kidney transplant rejection, prophylaxis; Liver transplant rejection, prophylaxis
|
|
| ALT_DEFINITION |
A drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
|
|
| alternative_term |
Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone FK 506 Fujimycin Hecoria Prograf Protopic TACROLIMUS Tacrolimus tacrolimus
|
|
| CAS_Registry |
109581-93-3
|
|
| CHEBI_ID |
CHEBI:61057
|
|
| Chemical_Formula |
C44H69NO12.H2O
|
|
| code |
C1311
|
|
| Contributing_Source |
CTRP FDA
|
|
| definition |
A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.
|
|
| Display_Name |
Tacrolimus
|
|
| FDA_UNII_Code |
WM0HAQ4WNM
|
|
| fromPubMed |
true
|
|
| imported from | ||
| in_subset |
http://purl.oboInOwllibrary.org/oboInOwl/NCIT_C116977 |
|
| label |
Tacrolimus
|
|
| Legacy_Concept_Name |
Tacrolimus
|
|
| NSC_Code |
717865
|
|
| oboInOwl:hasDbXRef | ||
| PDQ_Closed_Trial_Search_ID |
42009
|
|
| PDQ_Open_Trial_Search_ID |
42009
|
|
| preferred label |
Tacrolimus
|
|
| Preferred_Name |
Tacrolimus
|
|
| prefixIRI |
NCIT:C1311
|
|
| prefLabel |
Tacrolimus
|
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance
|
|
| textual definition |
A macrolide isolated from Streptomyces tsukubaensis. Tacrolimus binds to the FKBP-12 protein and forms a complex with calcium-dependent proteins, thereby inhibiting calcineurin phosphatase activity and resulting in decreased cytokine production. This agent exhibits potent immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation. Tacrolimus possesses similar immunosuppressive properties to cyclosporine, but is more potent.
|
|
| UMLS_CUI |
C0085149
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |